BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12110621)

  • 1. Smoking, lung cancers and their TP53 mutations.
    Cooper CS
    Mutagenesis; 2002 Jul; 17(4):279-80. PubMed ID: 12110621
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
    Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
    Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
    Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
    Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex analysis of the p53 tumor suppressor in lung carcinoma.
    Smardova J; Liskova K; Ravcukova B; Malcikova J; Hausnerova J; Svitakova M; Hrabalkova R; Zlamalikova L; Stano-Kozubik K; Blahakova I; Speldova J; Jarkovsky J; Smarda J
    Oncol Rep; 2016 Mar; 35(3):1859-67. PubMed ID: 26718964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation, allelism and survival in non-small cell lung cancer.
    Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
    Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.
    Zienolddiny S; Ryberg D; Arab MO; Skaug V; Haugen A
    Br J Cancer; 2001 Jan; 84(2):226-31. PubMed ID: 11161381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.
    Tornesello ML; Buonaguro L; Buonaguro FM
    Gynecol Oncol; 2013 Mar; 128(3):442-8. PubMed ID: 23168175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
    Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
    Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for common clonal origin of multifocal lung cancers.
    Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
    J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer.
    Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT
    Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors.
    Hou SM; Ryk C; Kannio A; Angelini S; Fält S; Nyberg F; Husgafvel-Pursiainen K
    Environ Mol Mutagen; 2003; 41(1):37-42. PubMed ID: 12552590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
    Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
    Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients.
    Kondo K; Tsuzuki H; Sasa M; Sumitomo M; Uyama T; Monden Y
    J Surg Oncol; 1996 Jan; 61(1):20-6. PubMed ID: 8544455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats.
    Kitada H; Tsutsumi M; Tsujiuchi T; Takahama M; Fukuda T; Narita N; Konsihi Y
    Mol Carcinog; 1996 Apr; 15(4):276-83. PubMed ID: 8634086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis.
    Przygodzki RM; Koss MN; Moran CA; Langer JC; Swalsky PA; Fishback N; Bakker A; Finkelstein SD
    Am J Clin Pathol; 1996 Oct; 106(4):487-92. PubMed ID: 8853037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.